Literature DB >> 26439443

Exercise Pills: At the Starting Line.

Shunchang Li1, Ismail Laher2.   

Abstract

Sedentary lifestyles, limited physical exercise, and prolonged inactivity undoubtedly increase chronic diseases, including obesity, type 2 diabetes, and cardiovascular diseases. It is widely acknowledged that exercise induces a number of physiological adaptations that have beneficial effects in the prevention and treatment of these chronic metabolic diseases. Unfortunately, exercise compliance is extremely low and often not possible. The development of exercise science and molecular techniques has increased our understanding of the molecular pathways responsive to exercise. Knowledge of these molecular targets has led to the development of chemical interventions that can mimic the beneficial effects of exercise without requiring actual muscle activity. This review focuses on the concept of 'exercise pills' and how they mimic the effects produced by physical exercise including oxidative fiber-type transformation, mitochondrial biogenesis, increased fat oxidation, angiogenesis, and improvement of exercise capacity. We also review candidate exercise pills, and contrast the beneficial effects and molecular mechanisms between physical exercise and exercise pills.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26439443     DOI: 10.1016/j.tips.2015.08.014

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  22 in total

1.  Myricetin improves endurance capacity by inducing muscle fiber type conversion via miR-499.

Authors:  Luting Wu; Li Ran; Hedong Lang; Min Zhou; Li Yu; Long Yi; Jundong Zhu; Lei Liu; Mantian Mi
Journal:  Nutr Metab (Lond)       Date:  2019-05-02       Impact factor: 4.169

Review 2.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

3.  β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.

Authors:  Ignatios Ikonomidis; Konstantinos Katogiannis; Elias Kyriakou; Maria Taichert; Georgios Katsimaglis; Maria Tsoumani; Ioanna Andreadou; Eirini Maratou; Vaia Lambadiari; Foteini Kousathana; Anna Papadopoulou; Charalampos Varlamos; Panagiotis Plotas; John Parissis; Kimon Stamatelopoulos; Dimitrios Alexopoulos; George Dimitriadis; Argirios E Tsantes
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

4.  MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose.

Authors:  Jon-Philippe K Hyatt
Journal:  Physiol Rep       Date:  2022-07

Review 5.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 6.  MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.

Authors:  Changhan Lee; Kyung Hwa Kim; Pinchas Cohen
Journal:  Free Radic Biol Med       Date:  2016-05-20       Impact factor: 7.376

Review 7.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

8.  MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats.

Authors:  Shunchang Li; Manda Wang; Jiacheng Ma; Xiaoli Pang; Jinghan Yuan; Yanrong Pan; Yu Fu; Ismail Laher
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-17       Impact factor: 5.555

9.  In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011.

Authors:  Lore Geldof; Koen Deventer; Kris Roels; Eva Tudela; Peter Van Eeno
Journal:  Int J Mol Sci       Date:  2016-10-03       Impact factor: 5.923

Review 10.  Caloric restriction and exercise "mimetics'': Ready for prime time?

Authors:  Christoph Handschin
Journal:  Pharmacol Res       Date:  2015-12-02       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.